Metastatic Colorectal Cancers

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

DrugDrug NameDrug Description
DB08885AfliberceptAflibercept is a recombinant fusion protein that comprises of two main components: the vascular endothelial growth factor (VEGF) binding portions from the extracellular domains of human VEGF receptors 1 and 2 which is then fused to the Fc portion of human IgG1. Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. FDA approved in November 18, 2011 and EMA approved in November 2012.
DB11596LevoleucovorinLevoleucovorin is the enantiomerically active form of Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin). Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. Despite this difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side effects (Kovoor et al, 2009). As folate analogs, levoleucovorin and leucovorin are both used to counteract the toxic effects of folic acid antagonists, such as methotrexate, which act by inhibiting the enzyme dihydrofolate reductase (DHFR). They are indicated for use as rescue therapy following use of high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Levoleucovorin, as the product Fusilev (FDA), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects of methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects.
DB01269PanitumumabPanitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
DB09343TipiracilTipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.[A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF or anti-EGFR therapy.[A31254]
DrugDrug NamePhaseStatusCount
DB125527-ethyl-10-hydroxycamptothecin1Completed1
DB08885Aflibercept1Completed1
DB11595Atezolizumab1Not Yet Recruiting1
DB00112Bevacizumab1Active Not Recruiting2
DB00112Bevacizumab1Completed4
DB00112Bevacizumab1Recruiting2
DB00112Bevacizumab1Terminated1
DB05985Binimetinib1Completed1
DB12737Brontictuzumab1Completed1
DB11666Buparlisib1Completed1
DB01101Capecitabine1Completed4
DB01101Capecitabine1Enrolling by Invitation1
DB01101Capecitabine1Recruiting1
DB11791Capmatinib1Terminated1
DB00002Cetuximab1Completed1
DB00002Cetuximab1Terminated1
DB00531Cyclophosphamide1Recruiting1
DB01254Dasatinib1Completed1
DB12349Dulanermin1Completed1
DB01590Everolimus1Completed1
DB01099Flucytosine1Recruiting1
DB00544Fluorouracil1Completed4
DB00544Fluorouracil1Recruiting1
DB04901Galiximab1Recruiting1
DB11918Guadecitabine1Recruiting1
DB00762Irinotecan1Active Not Recruiting1
DB00762Irinotecan1Completed3
DB00762Irinotecan1Enrolling by Invitation1
DB00762Irinotecan1Recruiting2
DB12331Labetuzumab govitecan1Completed1
DB01259Lapatinib1Completed1
DB00650Leucovorin1Completed2
DB00650Leucovorin1Recruiting1
DB12674Lurbinectedin1Completed1
DB04835Maraviroc1Not Yet Recruiting1
DB12155Napabucasin1Completed1
DB12634Navicixizumab1Recruiting1
DB09035Nivolumab1Recruiting1
DB00526Oxaliplatin1Completed3
DB00526Oxaliplatin1Recruiting1
DB01269Panitumumab1Completed1
DB09037Pembrolizumab1Not Yet Recruiting1
DB06809Plerixafor1Recruiting1
DB08896Regorafenib1Recruiting1
DB09143Sonidegib1Completed1
DB00398Sorafenib1Completed1
DB00398Sorafenib1Terminated1
DB09343Tipiracil1Completed1
DB00432Trifluridine1Completed1
DB08881Vemurafenib1Completed1
DB13896talimogene laherparepvec1Not Yet Recruiting1
DB12775Abituzumab1 / 2Completed1
DB08885Aflibercept1 / 2Completed1
DB08885Aflibercept1 / 2Terminated1
DB00928Azacitidine1 / 2Not Yet Recruiting1
DB00112Bevacizumab1 / 2Completed2
DB11967Binimetinib1 / 2Completed1
DB01101Capecitabine1 / 2Active Not Recruiting1
DB01101Capecitabine1 / 2Completed1
DB01101Capecitabine1 / 2Terminated1
DB04849Cediranib1 / 2Completed1
DB12033Cediranib1 / 2Completed1
DB00002Cetuximab1 / 2Completed5
DB11646Conatumumab1 / 2Completed2
DB11718Encorafenib1 / 2Completed1
DB12342Ensituximab1 / 2Completed1
DB11717Epacadostat1 / 2Not Yet Recruiting1
DB00544Fluorouracil1 / 2Active Not Recruiting1
DB00544Fluorouracil1 / 2Completed1
DB00762Irinotecan1 / 2Active Not Recruiting1
DB00762Irinotecan1 / 2Completed3
DB00762Irinotecan1 / 2Recruiting1
DB12331Labetuzumab govitecan1 / 2Recruiting1
DB00650Leucovorin1 / 2Active Not Recruiting1
DB00650Leucovorin1 / 2Completed1
DB12155Napabucasin1 / 2Recruiting1
DB00526Oxaliplatin1 / 2Active Not Recruiting1
DB00526Oxaliplatin1 / 2Completed1
DB00526Oxaliplatin1 / 2Terminated1
DB01269Panitumumab1 / 2Active Not Recruiting1
DB01269Panitumumab1 / 2Completed3
DB01269Panitumumab1 / 2Recruiting1
DB09037Pembrolizumab1 / 2Not Yet Recruiting1
DB09037Pembrolizumab1 / 2Recruiting2
DB11972Rilotumumab1 / 2Completed1
DB00398Sorafenib1 / 2Completed1
DB12200Tivantinib1 / 2Completed1
DB11771Tremelimumab1 / 2Recruiting1
DB08916Afatinib2Active Not Recruiting1
DB08885Aflibercept2Completed2
DB08885Aflibercept2Not Yet Recruiting2
DB08885Aflibercept2Recruiting4
DB08885Aflibercept2Terminated2
DB08885Aflibercept2Withdrawn2
DB00041Aldesleukin2Recruiting1
DB00026Anakinra2Active Not Recruiting1
DB11595Atezolizumab2Not Yet Recruiting1
DB11945Avelumab2Not Yet Recruiting2
DB11945Avelumab2Recruiting1
DB00928Azacitidine2Active Not Recruiting1
DB00443Betamethasone2Completed1
DB00112Bevacizumab2Active Not Recruiting4
DB00112Bevacizumab2Completed14
DB00112Bevacizumab2Not Yet Recruiting2
DB00112Bevacizumab2Recruiting7
DB00112Bevacizumab2Terminated2
DB00112Bevacizumab2Unknown Status3
DB00112Bevacizumab2Withdrawn2
DB05916CT-0112Completed1
DB01373Calcium2Unknown Status1
DB06724Calcium Carbonate2Unknown Status1
DB01101Capecitabine2Active Not Recruiting2
DB01101Capecitabine2Completed11
DB01101Capecitabine2Recruiting4
DB01101Capecitabine2Terminated5
DB01101Capecitabine2Unknown Status2
DB01101Capecitabine2Withdrawn4
DB00482Celecoxib2Terminated1
DB00482Celecoxib2Withdrawn1
DB00002Cetuximab2Active Not Recruiting5
DB00002Cetuximab2Completed9
DB00002Cetuximab2Not Yet Recruiting2
DB00002Cetuximab2Recruiting4
DB00002Cetuximab2Terminated6
DB00002Cetuximab2Unknown Status4
DB00002Cetuximab2Withdrawn1
DB11121Chloroxylenol2Completed1
DB05239Cobimetinib2Not Yet Recruiting1
DB11646Conatumumab2Completed1
DB00531Cyclophosphamide2Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting2
DB11840Dalotuzumab2Completed1
DB11840Dalotuzumab2Withdrawn1
DB11727Endostar2Unknown Status1
DB00530Erlotinib2Active Not Recruiting1
DB00530Erlotinib2Terminated2
DB00530Erlotinib2Unknown Status1
DB01590Everolimus2Completed1
DB11741Famitinib2Unknown Status1
DB08917Ferric Carboxymaltose2Recruiting1
DB01073Fludarabine2Recruiting1
DB00544Fluorouracil2Active Not Recruiting4
DB00544Fluorouracil2Completed11
DB00544Fluorouracil2Not Yet Recruiting3
DB00544Fluorouracil2Recruiting9
DB00544Fluorouracil2Terminated3
DB00544Fluorouracil2Unknown Status1
DB00544Fluorouracil2Withdrawn3
DB00158Folic Acid2Recruiting1
DB04901Galiximab2Not Yet Recruiting1
DB12205Ganitumab2Completed1
DB11896Gedatolisib2Terminated1
DB00317Gefitinib2Withdrawn1
DB00441Gemcitabine2Completed2
DB00441Gemcitabine2Terminated1
DB00762Irinotecan2Active Not Recruiting5
DB00762Irinotecan2Completed17
DB00762Irinotecan2Not Yet Recruiting4
DB00762Irinotecan2Recruiting11
DB00762Irinotecan2Terminated6
DB00762Irinotecan2Unknown Status4
DB00762Irinotecan2Withdrawn2
DB01592Iron2Recruiting1
DB00130L-Glutamine2Completed1
DB12331Labetuzumab govitecan2Unknown Status1
DB00709Lamivudine2Recruiting1
DB01259Lapatinib2Completed1
DB01259Lapatinib2Recruiting1
DB00650Leucovorin2Active Not Recruiting3
DB00650Leucovorin2Completed8
DB00650Leucovorin2Not Yet Recruiting3
DB00650Leucovorin2Recruiting5
DB00650Leucovorin2Terminated2
DB00650Leucovorin2Unknown Status2
DB00650Leucovorin2Withdrawn4
DB11596Levoleucovorin2Not Yet Recruiting1
DB11231Lycopene2Recruiting1
DB00331Metformin2Completed1
DB00563Methotrexate2Terminated1
DB05774Necitumumab2Completed1
DB09559Necitumumab2Completed1
DB00526Oxaliplatin2Active Not Recruiting2
DB00526Oxaliplatin2Completed14
DB00526Oxaliplatin2Not Yet Recruiting2
DB00526Oxaliplatin2Recruiting9
DB00526Oxaliplatin2Terminated2
DB00526Oxaliplatin2Unknown Status5
DB00526Oxaliplatin2Withdrawn4
DB01269Panitumumab2Active Not Recruiting1
DB01269Panitumumab2Completed10
DB01269Panitumumab2Not Yet Recruiting3
DB01269Panitumumab2Recruiting4
DB01269Panitumumab2Terminated2
DB01269Panitumumab2Unknown Status2
DB09037Pembrolizumab2Active Not Recruiting1
DB09037Pembrolizumab2Not Yet Recruiting1
DB09037Pembrolizumab2Recruiting2
DB00642Pemetrexed2Active Not Recruiting1
DB00642Pemetrexed2Completed2
DB00642Pemetrexed2Terminated1
DB00790Perindopril2Active Not Recruiting1
DB06366Pertuzumab2Recruiting1
DB08896Regorafenib2Active Not Recruiting4
DB08896Regorafenib2Recruiting5
DB08877Ruxolitinib2Active Not Recruiting1
DB12183Sapitinib2Active Not Recruiting1
DB00020Sargramostim2Not Yet Recruiting1
DB11689Selumetinib2Completed1
DB00641Simvastatin2Completed1
DB00398Sorafenib2Active Not Recruiting1
DB00398Sorafenib2Completed1
DB01268Sunitinib2Completed1
DB01268Sunitinib2Terminated1
DB08937TAS-1022Completed1
DB09256Tegafur2Completed1
DB09327Tegafur-uracil2Completed1
DB00853Temozolomide2Recruiting1
DB06287Temsirolimus2Completed1
DB04900Thymalfasin2Not Yet Recruiting1
DB09343Tipiracil2Completed1
DB12200Tivantinib2Active Not Recruiting1
DB00072Trastuzumab2Recruiting1
DB12056Trebananib2Completed1
DB11771Tremelimumab2Recruiting2
DB08604Triclosan2Completed1
DB00432Trifluridine2Completed1
DB03419Uracil2Completed1
DB08828Vismodegib2Completed2
DB00495Zidovudine2Recruiting1
DB08885Aflibercept2 / 3Withdrawn1
DB11885Anlotinib2 / 3Active Not Recruiting1
DB00544Fluorouracil2 / 3Completed1
DB00762Irinotecan2 / 3Completed2
DB00650Leucovorin2 / 3Completed1
DB05308ANX-5103Unknown Status1
DB08885Aflibercept3Completed2
DB00112Bevacizumab3Active Not Recruiting3
DB00112Bevacizumab3Completed3
DB00112Bevacizumab3Recruiting2
DB00112Bevacizumab3Unknown Status3
DB01101Capecitabine3Completed1
DB01101Capecitabine3Recruiting1
DB01101Capecitabine3Terminated1
DB01101Capecitabine3Unknown Status2
DB04849Cediranib3Completed1
DB12033Cediranib3Completed1
DB00002Cetuximab3Active Not Recruiting3
DB00002Cetuximab3Completed3
DB00002Cetuximab3Recruiting1
DB00002Cetuximab3Unknown Status1
DB11121Chloroxylenol3Active Not Recruiting1
DB01234Dexamethasone3Recruiting1
DB00254Doxycycline3Unknown Status1
DB00530Erlotinib3Completed1
DB11741Famitinib3Active Not Recruiting1
DB00322Floxuridine3Recruiting1
DB00544Fluorouracil3Active Not Recruiting1
DB00544Fluorouracil3Completed4
DB00544Fluorouracil3Not Yet Recruiting2
DB00544Fluorouracil3Recruiting2
DB00544Fluorouracil3Suspended1
DB00544Fluorouracil3Unknown Status1
DB00762Irinotecan3Active Not Recruiting1
DB00762Irinotecan3Completed4
DB00762Irinotecan3Not Yet Recruiting2
DB00762Irinotecan3Recruiting1
DB00762Irinotecan3Suspended1
DB00762Irinotecan3Unknown Status1
DB00650Leucovorin3Active Not Recruiting1
DB00650Leucovorin3Completed5
DB00650Leucovorin3Not Yet Recruiting1
DB00650Leucovorin3Recruiting2
DB00650Leucovorin3Unknown Status1
DB00526Oxaliplatin3Active Not Recruiting2
DB00526Oxaliplatin3Completed4
DB00526Oxaliplatin3Not Yet Recruiting1
DB00526Oxaliplatin3Recruiting1
DB00526Oxaliplatin3Suspended1
DB01269Panitumumab3Active Not Recruiting1
DB01269Panitumumab3Completed3
DB01269Panitumumab3Not Yet Recruiting1
DB00019Pegfilgrastim3Completed1
DB08896Regorafenib3Completed1
DB08896Regorafenib3Recruiting1
DB08896Regorafenib3Withdrawn1
DB01268Sunitinib3Completed1
DB00002Cetuximab4Active Not Recruiting1
DB00965Ethiodized oil4Recruiting1
DB00762Irinotecan4Completed1
DB00526Oxaliplatin4Recruiting1
DB00293Raltitrexed4Recruiting1
DB00112BevacizumabNot AvailableCompleted3
DB00112BevacizumabNot AvailableRecruiting4
DB01101CapecitabineNot AvailableCompleted1
DB01101CapecitabineNot AvailableUnknown Status1
DB00002CetuximabNot AvailableActive Not Recruiting1
DB00002CetuximabNot AvailableCompleted3
DB00544FluorouracilNot AvailableCompleted1
DB00544FluorouracilNot AvailableRecruiting1
DB09374Indocyanine greenNot AvailableCompleted1
DB00762IrinotecanNot AvailableCompleted2
DB00762IrinotecanNot AvailableRecruiting1
DB00650LeucovorinNot AvailableCompleted1
DB00650LeucovorinNot AvailableRecruiting1
DB00526OxaliplatinNot AvailableCompleted1
DB01269PanitumumabNot AvailableCompleted1
DB01269PanitumumabNot AvailableRecruiting1
DB00818PropofolNot AvailableRecruiting1
DB08896RegorafenibNot AvailableActive Not Recruiting1
DB08896RegorafenibNot AvailableCompleted1
DB00899RemifentanilNot AvailableRecruiting1
DB01236SevofluraneNot AvailableRecruiting1
DB08937TAS-102Not AvailableApproved for Marketing1